Challenges in setting up the antiretroviral paediatric registry in South Africa: Lessons learned from Free State Province clinics
DOI:
https://doi.org/10.7196/SAMJ.2024.v114i7.2115Keywords:
HIV, pediatric, adverse drug reactionsAbstract
-
References
Archary M, Van Zyl R, Sipambo N, Sorour G. Opinion paper: Optimised paediatric antiretroviral treatment to achieve the 95-95-95 goals. South Afr J HIV Med 2021;22(1):a1278. https://doi. org/10.4102/ sajhivmed. v22i1.1278
UNAIDS. AIDS and the Sustainable Development Goals. Geneva: UNAIDS, 2024. https://www. unaids.org/en/AIDS_SDGs#:~:text=A%20core%20principle%20of%20the,health%20and%20 vulnerability%2C%20being%20addressed (accessed 16 June /2024).
Van Liere GA, Lilian R, Dunlop J, et al. 2021. High rate of loss to follow-up and virological non-suppression in HIV-infected children on antiretroviral therapy highlights the need to improve quality of care in South Africa. Epidemiol Infect 2021;149:e88. https://doi.org/10.1017/ S0950268821000637
World Data Atlas 2021. https://www.unaids.org/sites/default/files/media_asset/2020_aids-data-book_ en.pdf (accessed 31 March /2024).
Joint United Nations Programme on Hiv/Aids (UNAIDS). UNAIDS Data 2023. https://www.unaids. org/en/resources/documents/2024/unaids-data (accessed 30 March 2024).
Ngoyi K, Hlabyago K, Ogunbanjo G, Steyn C, Bongongo, T. Prevalent clinical assessments of HIV positive infants in a South African district hospital. Open Public Health J 2024;17(1):E18749445278115. https://doi.org/10.2174/0118749445278115231228054735
Escosa-García L, Sainz T. HIV and ART in children. Front Pediatr 2022;10:1074684. https://doi. org/10.3389/fped.2022.1074684
Malinga S, Khan A, Archary M. Breaking the unbreakable: A paediatric case of dolutegravir resistance from KwaZulu-Natal. South Afr J HIV Med 2023; 24(1):1458.
Amuge P, Lugemwa A. Wynne B, et al. Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial. The Lancet HIV, 2022;9(9):e638-e648. https://doi.org/10.1016/S2352- 3018(22)00163-1
Downloads
Published
Issue
Section
License
Copyright (c) 2024 B R Omotoso, R Baleni, M Dheda, T Mofokeng
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Licensing Information
The SAMJ is published under an Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
Publishing Rights
Authors grant the Publisher the exclusive right to publish, display, reproduce and/or distribute the Work in print and electronic format and in any medium known or hereafter developed, including for commercial use. The Author also agrees that the Publisher may retain in print or electronic format more than one copy of the Work for the purpose of preservation, security and back-up.
